Hematological Neoplasms

New Advances in Chinese CAR-T Cell Therapy: CD27 Armored BCMA CAR-T Shows Potential in Treating Relapsed Multiple Myeloma

**New Advances in Chinese CAR-T Cell Therapy: CD27 Armored BCMA CAR-T Shows Potential in Treating Relapsed Multiple Myeloma** #BCMA #CD27#CARTCellTherapy #RRMM #MM #MultipleMyeloma #CART Relapsed and refractory multiple myeloma (RRMM) is a challenging blood cancer that poses significant obstacles for patients. Although several BCMA (B-cell maturation antigen) targeting CAR-T cell therapies have been developed, achieving Read More

November 5th,2024 Myeloma

CAR-T Cell Therapy as a New Option for Treating Multiple Myeloma

**CAR-T  Cell Therapy as a New Option for Treating Multiple Myeloma** “CAR-T cell therapy has now become a new option for treating patients with relapsed and refractory multiple myeloma, with hopes of changing the difficult situation in myeloma treatment where treatments are either ineffective or unavailable,” said Jin Jie, Director of the Hematology Department at the Read More

November 4th,2024 Myeloma , CAR-T

China’s CAR-T Therapy: A Beacon of Hope for Children with Acute Lymphoblastic Leukemia (ALL)

China’s CAR-T Therapy: A Beacon of Hope for Children with Acute Lymphoblastic Leukemia (ALL)  #CARTTherapy #Leukemia #ChildhoodCancer #ALL #CART #AcuteLymphoblasticLeukemia #Patientstory China’s CAR-T cell therapy is emerging as a beacon of hope in the fight against cancer, bringing unprecedented treatment possibilities. As a precise cellular immunotherapy, CAR-T therapy enhances the cancer-fighting abilities of T-cells through genetic editing technology, Read More

November 1st,2024 Leukemia , CAR-T , patient story

China’s CAR-T Therapy as a Beacon of Hope: A New Light for Multiple Myeloma Patients

**China’s CAR-T Therapy as a Beacon of Hope: A New Light for Multiple Myeloma Patients** #CAR-TTherapy #MultipleMyeloma #PatientStory #CancerSurvivor In recent years, CAR-T cell therapy in China has spearheaded a revolution in hematologic cancer treatment. This innovative immunotherapy has brought a glimmer of hope to many patients, especially those with relapsed and refractory cases who Read More

October 31st,2024 Myeloma , CAR-T

China’s New CAR-T Therapy: Bringing New Hope for Acute Myeloid Leukemia (AML)

**China’s New CAR-T Therapy: Bringing New Hope for Acute Myeloid Leukemia (AML)** #CLL1CART #AML #Leukemia #CART #CARTtherapy #AcuteMyeloidLeukemia #CLL1 #CD371 In recent years, China’s rise in the field of medical innovation has been remarkable, especially with breakthroughs in cancer and hematologic malignancy treatments that are drawing global attention. Today, we are introducing a cutting-edge treatment from China—donor-derived CLL-1 Read More

October 29th,2024 Leukemia , CAR-T

Beacon of Hope: China’s CAR-T Therapy Helps a TP53-Deficient Diffuse Large B-Cell Lymphoma(DLBCL) Patient Achieve Complete Remission

### Beacon of Hope: China’s CAR-T Therapy Helps a TP53-Deficient Diffuse Large B-Cell Lymphoma Patient Achieve Complete Remission #CAR-T #CancerTreatment #Lymphoma #DLBCL #PrecisionMedicine In an inspiring treatment case, a 38-year-old Chinese male patient with TP53-deficient Diffuse Large B-cell Lymphoma (DLBCL) achieved complete remission through Chinese CAR-T cell therapy. This remarkable outcome has sparked excitement about Read More

October 29th,2024 Lymphoma , CAR-T

Significant Progress in CAR-T Therapy in China: Long-Term Effects of Combined CD19 and CD22 Treatment for Acute B-Lymphoblastic Leukemia

### Significant Progress in CAR-T Therapy in China: Long-Term Effects of Combined CD19 and CD22 Treatment for Acute B-Lymphoblastic Leukemia #ALL #CAR-Ttherapy #Leukemia #CancerResearch #B_ALL #LeukemiaTreatment Recently, a Chinese medical team published a notable study titled “Five-year outcome of CD19 combined with CD22 CAR-T cell therapy in B-ALL patients relapsed after allo-transplantation.” The research highlights Read More

October 28th,2024 Leukemia , CAR-T

Another New CAR-T Therapy in China is Fast-Tracking Approval, Targeting Pediatric Acute Lymphoblastic Leukemia(ALL) with a 100% Response Rate!

Another New CAR-T Therapy in China is Fast-Tracking Approval, Targeting Pediatric Acute Lymphoblastic Leukemia with a 100% Response Rate! #ALL #AcuteLymphoblasticLeukemia #Leukemia #CART #CARTtherapy In recent years, CAR-T cell therapies from China have garnered global attention in the fight against cancer, and now another CAR-T product is about to hit the market. Priscabtagene Autoleucel Injection Read More

October 25th,2024 Leukemia , CAR-T

What Kind of Multiple Myeloma Patients Are Suitable for CAR-T Therapy in China?

# What Kind of Multiple Myeloma Patients Are Suitable for CAR-T Therapy in China? #MultipleMyeloma #CAR_Therapy #MM #CART #RRMM #Hematology **Multiple Myeloma** (MM) is a malignant hematological disease that affects plasma cells. In recent years, various drugs and treatment methods, such as proteasome inhibitors, immunomodulatory drugs, and autologous stem cell transplantation, have significantly improved the Read More

October 24th,2024 Myeloma , CAR-T

Recommended Myeloma Expert – Professor Qiu Luguo – A Leading Specialist in Hematology and Multiple Myeloma

### Recommended Myeloma Expert – Professor Qiu Luguo – A Leading Specialist in Hematology and Multiple Myeloma We at Advanced Medicine In China are proud to have Professor Qiu Luguo as our contracted expert. He provides telemedicine consultations for our international patients and can arrange for them to travel to China through a special fast-track Read More

October 23rd,2024 Myeloma

Complete Remission In Just Two Months! China’s CAR-T Therapy Brings New Hope For Lymphoma (DLBCL) Patients!

Complete Remission In Just Two Months! China’s CAR-T Therapy Brings New Hope For Lymphoma (DLBCL) Patients! #Lymphoma #CAR_TCellTherapy #DLBCL#CancerHope #PatientStory Lymphoma has long been regarded as a “synonym for death,” with its high incidence and recurrence rates striking fear into many. However, with the rapid advancement of medical technology, a revolutionary new therapy is changing this Read More

October 23rd,2024 Lymphoma , CAR-T , patient story

China’s CAR-T Cell Therapy: Leading a New Revolution in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma (MCL)

  #CARTCellTherapy #MantleCellLymphoma #RelapsedMCL #RefractoryMCL #Hematology #MCL Mantle Cell Lymphoma (MCL), a rare and complex subtype of non-Hodgkin’s lymphoma, exhibits both aggressive and indolent characteristics. Since MCL patients are usually diagnosed at an advanced stage, often with poor prognostic factors, traditional treatments such as chemotherapy and immunotherapy have brought survival benefits to some patients. However, most Read More

October 23rd,2024 Lymphoma